Statins and prevention of stent-related late adverse events.
First Department of Internal Medicine, Nara Medical University, Nara, Japan.
Shiro
S
Uemura
D003324:Coronary Artery Disease / Q000628:therapy*; D003331:Coronary Vessels / Q000187:drug effects*; D054855:Drug-Eluting Stents; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D058426:Neointima; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation*; D017035:Pravastatin / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D017035:Pravastatin